Last updated: February 17, 2026
What Is the Current Market Status for NDC 00536-1317?
NDC 00536-1317 corresponds to Doxorubicin Hydrochloride Injection, USP, a chemotherapy agent used primarily in oncology. The drug is a generic version of the branded product, initially marketed by Pfizer as Adriamycin. It has a widespread off-patent status, which influences its market dynamics. Although specific sales data for this NDC is restricted due to confidentiality agreements, overall trends for doxorubicin injections inform the market outlook.
How Does the Market Size and Competition for Doxorubicin Hydrochloride Injection Look?
The global oncology drug market is expanding, driven by increasing cancer incidence, with chemotherapy agents like doxorubicin constituting significant segments. Key points include:
- Market Size: The global anti-cancer drugs market was valued at approximately USD 140 billion in 2022, with chemotherapy agents accounting for about 35%.[1]
- Generic Penetration: The entry of generic doxorubicin injections has intensified price competition. Several manufacturers, including Teva, Sagent, and other regional suppliers, produce similar formulations.
- Pricing Trends: Generic doxorubicin injections in the US have experienced retail prices ranging from USD 50 to USD 150 per 50 mg vial, depending on the supplier, indicating a high price sensitivity due to competition.
- Supply Chain: Vendors with established manufacturing capabilities and regulatory approvals dominate distribution channels in North America and Europe.
What Are the Price Projections for NDC 00536-1317?
Price projection modeling depends on factors like regulatory landscape, patent status, manufacturing costs, and market entry barriers.
Short-term Outlook (Next 1-2 Years)
- Stable or Slight Decrease: Due to high competition, prices are unlikely to rise. A decrease of 2-5% annually is expected on average.
- Pricing Range: Currently, the approximate USP retail price per 50 mg vial is USD 75-120. Wholesale acquisition costs are often lower but vary by distribution channels.
Long-term Outlook (3-5 Years)
- Potential Price Decline: As more manufacturers enter the market, prices could decrease further, potentially reaching USD 50-80 per 50 mg vial.
- Market Saturation Impact: Increased biosimilar or new formulations could lead to further price erosion.
Influencing Factors
- Regulatory Approvals: New formulations or biosimilars can impact pricing.
- Market Dynamics: Healthcare system policies, especially in the US, influence reimbursement and pricing.
- Supply Constraints: Manufacturing disruptions or raw material shortages could temporarily affect pricing.
How Do Regulatory and Market Forces Affect Pricing?
- FDA Approvals: The absence of exclusivity periods for generics means unlimited market entry after patent expiry, driving prices down.
- Reimbursement Policies: US Medicare and private insurers favor lower-cost generics, reinforcing price competition.
- International Markets: In emerging markets, prices tend to be lower due to cost sensitivity and fewer regulatory barriers, but import tariffs and distribution costs affect final prices.
Conclusion
Doxorubicin Hydrochloride Injection (NDC 00536-1317) benefits from a mature generic market leading to competitive pricing. Short-term prices are stable with slight decline expectations, while further reductions are likely over the coming years due to market saturation and technological advances.
Key Takeaways
- The market for doxorubicin injections remains highly competitive, with multiple manufacturers.
- Current retail prices for 50 mg vials range between USD 75 and USD 120.
- Prices are expected to decline gradually to USD 50-80 over 3-5 years.
- Market entry of biosimilars or new formulations could accelerate price erosion.
- Regulatory and reimbursement policies heavily influence pricing trends.
FAQs
1. How does the patent status influence the price of NDC 00536-1317?
The patent for the original branded doxorubicin expired years ago, allowing multiple manufacturers to produce generic versions, driving prices downward.
2. Are there significant regional differences in pricing for this drug?
Yes. Prices tend to be higher in developed markets like the US and Europe and lower in emerging markets due to regulatory, economic, and competitive factors.
3. What impact could biosimilars have on the market?
Biosimilars could reduce prices further and increase access, especially if approved and widely adopted.
4. How might supply chain issues influence future prices?
Disruptions in raw material availability or manufacturing capacity can temporarily increase prices, but long-term effects depend on market response.
5. What factors could slow down price declines?
Regulatory barriers, supply shortages, or limited competition could stabilize prices despite market saturation.
Sources
[1] Global Oncology Drugs Market Report 2022. Market Research Future.
